Indo Us Bio-Tech Limited

Company Profile

Indo Us Bio-Tech Limited had its IPO on under the ticker symbol 541304.

The company operates in the Other sector and Other industry. Indo Us Bio-Tech Limited has a staff strength of 0 employees.

Stock update

Shares of Indo Us Bio-Tech Limited opened at ₹244.95 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹244.95 - ₹244.95, and closed at ₹244.95.

This is a +3.84% increase from the previous day's closing price.

A total volume of 1,000 shares were traded at the close of the day’s session.

In the last one week, shares of Indo Us Bio-Tech Limited have slipped by -9.66%.

Indo Us Bio-Tech Limited's Key Ratios

Indo Us Bio-Tech Limited has a market cap of ₹224.52 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months Indo Us Bio-Tech Limited’s revenue was ₹0 with a gross profit of ₹0 and an EBITDA of ₹0. The EBITDA ratio measures Indo Us Bio-Tech Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Indo Us Bio-Tech Limited’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 1698.02%.

In Q3.6666666666667, Indo Us Bio-Tech Limited’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Indo Us Bio-Tech Limited’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at ₹0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Indo Us Bio-Tech Limited’s profitability.

Indo Us Bio-Tech Limited stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

Indo Us Bio-Tech Limited stock pays annual dividends of ₹ per share, indicating a yield of None and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

₹685.04 million

Total Liabilities

₹135.96 million

Operating Cash Flow

₹-15464000.00

Capital Expenditure

₹5.03 million

Dividend Payout Ratio

0%

Indo Us Bio-Tech Limited ended 2025 with ₹685.04 million in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹685.04 million while shareholder equity stood at ₹503.42 million.

Indo Us Bio-Tech Limited ended 2025 with ₹0 in deferred long-term liabilities, ₹135.96 million in other current liabilities, 100260000.00 in common stock, ₹403.16 million in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹3.07 million and cash and short-term investments were ₹3.07 million. The company’s total short-term debt was ₹79,764,000 while long-term debt stood at ₹28.83 million.

Indo Us Bio-Tech Limited’s total current assets stands at ₹596.97 million while long-term investments were ₹0 and short-term investments were ₹0. Its net receivables were ₹346.62 million compared to accounts payable of ₹0 and inventory worth ₹207.16 million.

In 2025, Indo Us Bio-Tech Limited's operating cash flow was ₹-15464000.00 while its capital expenditure stood at ₹5.03 million.

Comparatively, Indo Us Bio-Tech Limited paid ₹0 in dividends in 2025.

Other key metrics

Current Trading Price

₹244.95

52-Week High

₹585

52-Week Low

₹88

Analyst Target Price

₹

Indo Us Bio-Tech Limited stock is currently trading at ₹244.95 per share. It touched a 52-week high of ₹585 and a 52-week low of ₹585. Analysts tracking the stock have a 12-month average target price of ₹.

Its 50-day moving average was ₹180.04 and 200-day moving average was ₹101.29 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.